Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.
Publication
, Conference
Morris, MJ; Loriot, Y; Beer, TM; Higano, CS; Armstrong, AJ; Sternberg, CN; De Bono, JS; Tombal, BF; Noonberg, SB; Mansbach, HH; Bhattacharya, S ...
Published in: Journal of Clinical Oncology
May 20, 2014
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5054 / 5054
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morris, M. J., Loriot, Y., Beer, T. M., Higano, C. S., Armstrong, A. J., Sternberg, C. N., … Rathkopf, D. E. (2014). Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. In Journal of Clinical Oncology (Vol. 32, pp. 5054–5054). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5054
Morris, Michael J., Yohann Loriot, Tomasz M. Beer, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann Sebastian De Bono, et al. “Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.” In Journal of Clinical Oncology, 32:5054–5054. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5054.
Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, et al. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5054–5054.
Morris, Michael J., et al. “Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5054–5054. Crossref, doi:10.1200/jco.2014.32.15_suppl.5054.
Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, De Bono JS, Tombal BF, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Rathkopf DE. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5054–5054.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5054 / 5054
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences